Please amend the subject application as follows:

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (Currently Amended) A composition which comprises:

(a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside ~~derivative~~ which comprises a converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ~~to~~ ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside; ~~an immunogenic protein,~~

(b) QS-21; ~~a carbohydrate derived from the bark of a Quillaja saponaria Molina tree,~~ and

(c) a pharmaceutically acceptable carrier,

wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the

~~amounts of such~~ conjugate and QS-21 are each present in the composition in an amount ~~such adjuvant being~~ effective to stimulate or enhance antibody production in a subject.[[,]]

~~wherein, in the conjugate the ganglioside derivative is conjugated to the immunogenic protein through a ceramide portion of the ganglioside.~~

2.-5. (Cancelled)

6. (Currently Amended) The composition of claim 1, wherein the amount of the conjugate ~~ganglioside~~ is ~~an amount~~ between about 3 μg and about 100 μg.

7. (Currently Amended) The composition of claim ~~5~~ 1, wherein the amount of QS-21 is ~~an amount~~ between about 30 μg and about 100 μg.

8. (Previously Presented) The composition of claim 1, wherein the subject is a human.

9.-10. (Cancelled)

11. (Currently Amended) A method of enhancing antibody production in a subject which comprises administering to the subject an effective antibody producing amount of ~~the~~ a composition ~~of claim 1,~~ comprising:

(a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside which comprises a

converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;

(b) QS-21; and

(c) a pharmaceutically acceptable carrier,

wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the conjugate and QS-21 are each present in the composition in an amount effective to stimulate or enhance antibody production in a subject. ~~so as to thereby enhance antibody production in the subject.~~

12.-13. (Cancelled)

14. (Currently Amended) A method of treating a small cell lung cancer in a subject which comprises administering to the subject an effective small cell lung cancer treating amount of a ~~the~~ composition ~~of claim 1,~~ comprising:

(a) a conjugate of i) a derivative of a fucosyl GM1 ganglioside which comprises a

converted ceramide portion, which differs from the ceramide portion of the fucosyl GM1 ganglioside solely by having an aldehyde group in place of a double bond, and ii) Keyhole Limpet Hemocyanin, wherein the derivative of fucosyl GM1 ganglioside is covalently conjugated to Keyhole Limpet Hemocyanin by a covalent bond between an amino group of Keyhole Limpet Hemocyanin and the aldehyde group of the converted ceramide portion of the fucosyl GM1 ganglioside;

(b) QS-21; and

(c) a pharmaceutically acceptable carrier,

wherein the fucosyl GM1 ganglioside derivative:Keyhole Limpet Hemocyanin molar ratio in the conjugate is from 400:1 to 1400:1; and the conjugate and QS-21 are each present in the composition in an amount effective to ~~so as to thereby~~ treat the small cell lung cancer in the subject.

15.-16. (Cancelled)